Skip to content

Biological Determinants of Sputum Rheology in Chronic Airway Diseases

Biological Determinants of Sputum Rheology in Chronic Airway Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04081740
Acronym
CADRhé
Enrollment
48
Registered
2019-09-09
Start date
2019-09-15
Completion date
2019-10-15
Last updated
2019-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Bronchiectasis, COPD

Brief summary

The primary objective of this study is to investigate the biological determinants of sputum rheology variations.

Detailed description

Secondarily, this study aims to compare rheology parameters between different chronic airway disease sub-populations.

Interventions

None listed

Sponsors

APARD Fonds de dotation
CollaboratorOTHER
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Affiliate with or beneficiary of the French national single-payer health insurance system * Patient capable of spontaneous mucus expectoration * Consulting or hospitalized at the study centre Inclusion Criteria for the Asthma Group * Never- or former-smoker (\<10 pack-years) * Medical history compatible with asthma * Reversible post-brochodilator (or post-corticosteroid test) ventilatory obstruction (ratio of forced expiratory volume in 1 second : forced vital capacity \< 70%) or significant variation in respiratory function -- OR -- Bronchial hyperresponsiveness demonstrated during a broncho-provocation test Inclusion Criteria for the COPD Group * Current- or former-smokers (\>10 pack years) * Chronic obstructive pulmonary disease according to GOLD criteria Inclusion Criteria for the Bronchiectasis Group * Presence of bronchiectasis on computed tomography scan * Cystic fibrosis has been ruled out

Exclusion criteria

* Patient expresses opposition to the protocol * Breast feeding or pregnant * Metastatic neoplastic disease * Other active pulmonary disease (tuberculosis, interstitial lung disease) * Recent psychiatric disorder (in the past year and documented via a specialist consult) * Consumption of illicit drugs or alcoholism * Patients in an exclusion period determined by another study * Patients under any type of legal guardianship * Prisoners * Impossible to correctly inform the patient * Does not fluently read French * Emergency situations

Design outcomes

Primary

MeasureTime frameDescription
Measurement of crossover stress (mucus rheology)Day 0The crossover stress point for each mucus sample will be measured in Pa.

Secondary

MeasureTime frameDescription
Measurement of the storage modulus (mucus rheology)Day 0The storage modulus point for each mucus sample will be measured in Pa.
Measurement of the loss modulus (mucus rheology)Day 0The loss modulus point for each mucus sample will be measured in Pa.
Measurement of the strain crossover (mucus rheology)Day 0The strain crossover point for each mucus sample will be measured in Pa.
Measurement of the loss factor (mucus rheology)Day 0The loss factor point for each mucus sample will be measured as a tangent to an angle in radians.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026